 Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 Santhera Pharmaceuticals SIX: SANN and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration FDA has accepted the new drug application NDA for vamorolone for the treatment of Duchenne muscular dystrophy DMD for filing. The FDA... The post Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy appeare... 